Question 1

Does ProShare Advisors own CHRS stock?

Accepted Answer

Yes. As of its Q3 2026 13F, ProShare Advisors holds 20,700 shares of CHRS (Coherus Oncology), worth $25,047.

Question 2

How many shares of CHRS does ProShare Advisors own?

Accepted Answer

As of its Q3 2026 13F, ProShare Advisors holds 20,700 shares of CHRS (Coherus Oncology).

Question 3

What is ProShare Advisors' CHRS position worth?

Accepted Answer

As of its Q3 2026 13F, ProShare Advisors' CHRS position is worth $25,047.

Question 4

Is ProShare Advisors buying or selling CHRS?

Accepted Answer

In Q3 2026, ProShare Advisors reduced its CHRS position by 1,472 shares (-6.6%).

Question 5

When did ProShare Advisors first buy CHRS?

Accepted Answer

ProShare Advisors already held CHRS in its Q4 2018 13F, the earliest on record, and has listed it in 32 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q3 Latest	Decreased	20,700	-6.6%	$25,047	0.0%	$1.21	0
2026-Q2	Increased	22,172	+2.2%	$31,040	0.0%	$1.40	14
2026-Q1	Decreased	21,700	-12.2%	$36,674	0.0%	$1.69	0
2025-Q4	Increased	24,718	+36.3%	$35,099	0.0%	$1.42	26
2025-Q3	Decreased	18,135	-16.6%	$29,741	0.0%	$1.64	0
2025-Q2	Decreased	21,748	-10.6%	$15,904	0.0%	$0.73	0
2025-Q1	Decreased	24,331	-22.4%	$19,635	0.0%	$0.81	0
2024-Q4	Increased	31,335	+12.6%	$43,242	0.0%	$1.38	23
2024-Q3	Increased	27,831	+31.6%	$28,945	0.0%	$1.04	25